Information ⬇
- Ischemic deficits of <3 h duration, with no hemorrhage by CT criteria, may benefit from thrombolytic therapy with IV recombinant tissue plasminogen activator (Table 17-3).
- Based on trial data, IV rtPA is used in many centers for deficits of 3-4.5 h duration, but is not yet approved for this window in the United States.
Outline ⬆